A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

Trial Profile

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Feb 2018 Planned number of patients changed from 96 to 100.
    • 08 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 26 Jan 2018 Planned initiation date changed from 15 Dec 2017 to 2 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top